• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Combined Rituximab and Daratumumab Treatment in Difficult-to-Treat Nephrotic Syndrome Cases.

作者信息

Angeletti Andrea, Bin Sofia, Kajana Xhuliana, Spinelli Sonia, Bigatti Carolina, Caridi Gianluca, Candiano Giovanni, Lugani Francesca, Verrina Enrico E, La Porta Edoardo, Magnasco Alberto, Bruschi Maurizio, Cravedi Paolo, Ghiggeri Gian Marco

机构信息

Nephrology, Dialysis and Transplantation Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.

Translational Transplant Research Center and Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

出版信息

Kidney Int Rep. 2024 Apr 4;9(6):1892-1896. doi: 10.1016/j.ekir.2024.04.006. eCollection 2024 Jun.

DOI:10.1016/j.ekir.2024.04.006
PMID:38899172
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11184257/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4548/11184257/d5cd8289ee7c/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4548/11184257/d7a3a97745ff/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4548/11184257/d5cd8289ee7c/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4548/11184257/d7a3a97745ff/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4548/11184257/d5cd8289ee7c/gr2.jpg

相似文献

1
Combined Rituximab and Daratumumab Treatment in Difficult-to-Treat Nephrotic Syndrome Cases.利妥昔单抗与达雷妥尤单抗联合治疗难治性肾病综合征病例
Kidney Int Rep. 2024 Apr 4;9(6):1892-1896. doi: 10.1016/j.ekir.2024.04.006. eCollection 2024 Jun.
2
Review of the Role of Rituximab in the Management of Adult Minimal Change Disease and Immune-Mediated Focal and Segmental Glomerulosclerosis.利妥昔单抗在成人微小病变病及免疫介导的局灶节段性肾小球硬化症治疗中的作用综述
Glomerular Dis. 2023 Aug 18;3(1):211-219. doi: 10.1159/000533695. eCollection 2023 Jan-Dec.
3
New and Old Anti-CD20 Monoclonal Antibodies for Nephrotic Syndrome. Where We Are?新型及旧型抗 CD20 单克隆抗体治疗肾病综合征：我们已走到哪一步？
Front Immunol. 2022 Feb 11;13:805697. doi: 10.3389/fimmu.2022.805697. eCollection 2022.
4
Efficacy of combined rituximab and daratumumab treatment in posttransplant recurrent focal segmental glomerulosclerosis.联合利妥昔单抗和达雷妥尤单抗治疗移植后复发局灶节段性肾小球硬化症的疗效。
Am J Transplant. 2024 Apr;24(4):688-692. doi: 10.1016/j.ajt.2023.12.010. Epub 2023 Dec 14.
5
Rituximab in adult minimal change disease and focal segmental glomerulosclerosis.利妥昔单抗治疗成人微小病变病和局灶节段性肾小球硬化症
Nephron Clin Pract. 2014;128(3-4):277-82. doi: 10.1159/000368590. Epub 2014 Nov 8.
6
Biologics in steroid resistant nephrotic syndrome in childhood: review and new hypothesis-driven treatment.儿童类固醇耐药性肾病综合征中的生物制剂：综述与新的假说驱动治疗。
Front Immunol. 2023 Aug 29;14:1213203. doi: 10.3389/fimmu.2023.1213203. eCollection 2023.
7
Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?利妥昔单抗在成人微小病变性肾病和局灶节段性肾小球硬化症中的应用：已知和未知的有哪些？
Autoimmun Rev. 2020 Nov;19(11):102671. doi: 10.1016/j.autrev.2020.102671. Epub 2020 Sep 15.
8
Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study.利妥昔单抗治疗成人频繁复发或激素依赖型肾病综合征伴微小病变性肾病和局灶节段性肾小球硬化的疗效：一项中国多中心回顾性研究。
Am J Nephrol. 2024;55(1):25-36. doi: 10.1159/000535010. Epub 2023 Nov 14.
9
Remission of steroid-resistant nephrotic syndrome due to focal and segmental glomerulosclerosis using rituximab.使用利妥昔单抗治疗局灶节段性肾小球硬化所致激素抵抗型肾病综合征的缓解情况。
Int Urol Nephrol. 2008;40(3):807-10. doi: 10.1007/s11255-008-9393-0. Epub 2008 May 20.
10
Nephrotic syndrome; is rituximab the light at the end of the tunnel in the treatment of adult steroid-dependent minimal change disease and focal segmental glomerulosclerosis?肾病综合征；利妥昔单抗是成人激素依赖型微小病变病和局灶节段性肾小球硬化症治疗中的曙光吗？
J Nephropathol. 2014 Jan;3(1):1-3. doi: 10.12860/jnp.2014.01. Epub 2014 Jan 1.

引用本文的文献

1
Complement and IgM in FSGS: Minor Characters or Leading Actors?局灶节段性肾小球硬化中的补体和IgM：小角色还是主角？
Kidney360. 2025 Aug 28;6(8):1265-1267. doi: 10.34067/KID.0000000814.
2
Advances in the treatment of ANCA-associated vasculitis.抗中性粒细胞胞浆抗体相关血管炎的治疗进展
Nat Rev Rheumatol. 2025 Jun 5. doi: 10.1038/s41584-025-01266-1.
3
Potential and pitfalls of measuring circulating anti-nephrin autoantibodies in glomerular diseases.测量肾小球疾病中循环抗肾足细胞蛋白自身抗体的潜力与陷阱

本文引用的文献

1
Biologics in steroid resistant nephrotic syndrome in childhood: review and new hypothesis-driven treatment.儿童类固醇耐药性肾病综合征中的生物制剂：综述与新的假说驱动治疗。
Front Immunol. 2023 Aug 29;14:1213203. doi: 10.3389/fimmu.2023.1213203. eCollection 2023.
2
Natural antibody and complement activation characterize patients with idiopathic nephrotic syndrome.天然抗体和补体激活可作为特发性肾病综合征的特征。
Am J Physiol Renal Physiol. 2021 Oct 1;321(4):F505-F516. doi: 10.1152/ajprenal.00041.2021. Epub 2021 Aug 30.
3
A global antiB cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome.
Clin Kidney J. 2025 Apr 12;18(5):sfaf100. doi: 10.1093/ckj/sfaf100. eCollection 2025 May.
4
Case report: Single infusion of combined anti-CD20 and anti-CD38 monoclonal antibodies in pediatric refractory lupus nephritis.病例报告：在儿童难治性狼疮性肾炎中单次输注联合抗CD20和抗CD38单克隆抗体
Front Immunol. 2025 Jan 28;16:1525892. doi: 10.3389/fimmu.2025.1525892. eCollection 2025.
5
Rituximab as a first-line therapy in children with new-onset idiopathic nephrotic syndrome.利妥昔单抗作为新发特发性肾病综合征儿童的一线治疗药物。
Clin Kidney J. 2024 Nov 18;18(1):sfae348. doi: 10.1093/ckj/sfae348. eCollection 2025 Jan.
6
Childhood idiopathic nephrotic syndrome: recent advancements shaping future guidelines.儿童特发性肾病综合征：塑造未来指南的最新进展
Pediatr Nephrol. 2024 Dec 26. doi: 10.1007/s00467-024-06634-9.
7
Management and long-term outcome of recurrent idiopathic FSGS in pediatric kidney transplant recipients.儿童肾移植受者复发性特发性 FSGS 的管理和长期预后。
Sci Rep. 2024 Oct 26;14(1):25493. doi: 10.1038/s41598-024-74184-z.
8
Difficult-to-Treat Nephrotic Syndrome in Childhood-Global Depletion of B-Cells.儿童难治性肾病综合征——B细胞的整体耗竭
Kidney Int Rep. 2024 May 7;9(7):1969-1971. doi: 10.1016/j.ekir.2024.04.064. eCollection 2024 Jul.
在严重小儿肾病综合征中联合奥滨尤妥珠单抗和达雷妥尤单抗的全球抗 B 细胞策略。
Pediatr Nephrol. 2021 May;36(5):1175-1182. doi: 10.1007/s00467-020-04811-0. Epub 2020 Oct 28.
4
Management of steroid-resistant nephrotic syndrome in children and adolescents.儿童和青少年类固醇耐药性肾病综合征的管理。
Lancet Child Adolesc Health. 2018 Dec;2(12):880-890. doi: 10.1016/S2352-4642(18)30283-9. Epub 2018 Oct 18.
5
Idiopathic nephrotic syndrome in children.儿童特发性肾病综合征。
Lancet. 2018 Jul 7;392(10141):61-74. doi: 10.1016/S0140-6736(18)30536-1. Epub 2018 Jun 14.
6
Clinical Significance of IgM and C3 Glomerular Deposition in Primary Focal Segmental Glomerulosclerosis.原发性局灶节段性肾小球硬化中IgM和C3肾小球沉积的临床意义
Clin J Am Soc Nephrol. 2016 Sep 7;11(9):1582-1589. doi: 10.2215/CJN.01190216. Epub 2016 Jun 23.
7
Long-term Kidney Transplant Outcomes in Primary Glomerulonephritis: Analysis From the ERA-EDTA Registry.原发性肾小球肾炎患者长期肾移植结局：来自欧洲肾脏最佳实践（ERA-EDTA）注册研究的分析
Transplantation. 2016 Sep;100(9):1955-62. doi: 10.1097/TP.0000000000000962.
8
Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO.KDIGO 发布类固醇敏感性肾病综合征治疗新指南
Pediatr Nephrol. 2013 Mar;28(3):415-26. doi: 10.1007/s00467-012-2310-x. Epub 2012 Oct 3.
9
Rituximab in children with resistant idiopathic nephrotic syndrome.利妥昔单抗治疗耐药性特发性肾病综合征患儿。
J Am Soc Nephrol. 2012 Jun;23(6):1117-24. doi: 10.1681/ASN.2011080775. Epub 2012 May 10.